An Ohio man and a Michigan couple who recently ate at Taco Bell are among the first victims to sue over the cyclospora outbreak that has sickened thousands and caused explosive diarrhea.
The Ohio man allegedly got sick after three June meals at the eatery, while the Michiganders said they became ill the same month from lettuce at the fast food joint – the ingredient blamed for about 90% of cases of Michigan Taco Bell customers getting sick, according to the Food and Drug Administration.
An attorney who represents food poisoning victims said he is fielding calls from scores of people who ate at Taco Bell and got sick. teracreonte – stock.adobe.com Mohammed Ayyad, a regular customer at a Taco Bell in North Olmsted, Ohio, said his troubles began with orders of Cheesy Fiesta Potatoes and Avocado Ranch Chicken Stackers he scarfed down over three visits in mid-June.
Days later, he developed a “severe” headache, chills, vomiting and persistent diarrhea that became so debilitating, he was unable to sleep, according to a complaint filed Thursday in Ohio federal court.
Nine days after his symptoms began, Ayyad sought treatment at an urgent care clinic, where he was prescribed Imodium instead of antibiotics, the lawsuit alleges.
By July 9, a stool test confirmed he had contracted the parasite. Ayyad missed two weeks of work, lost income and continues to suffer nausea and other symptoms, according to the complaint.
Taylor Farms said it’s Mexican operation is voluntarily removing all iceberg lettuce sourced from Central Mexico. ASSOCIATED PRESS The lawsuit names Vancouver, Wash.-based franchisee Pacific Bells LLC, which operates roughly 300 Taco Bell restaurants, as the defendant.
Ayyad’s attorney Bill Marler told The Post he plans to amend the complaint to add Salinas, Calif.-based Taylor Farms, identified by the Washington Post as the provider of the contaminated produce. More cases are in the works, he indicated.
Bill Marler is representing Taco Bell customers who contracted cyclosporiasis . Bill Marler/Facebook “We have been contacted by more than 30 people and 90% of them ate at Taco Bell,” Marler told The Post.
In a separate lawsuit filed Friday in Michigan federal court, Preston and Marie Parrish alleged they contracted cyclosporiasis after eating at a Taco Bell in Durand, Mich., on June 30. Their complaint names Taco Bell Corp., Taco Bell of America and Taylor Farms as defendants.
Taylor Farms, which supplies Taco Bell with shredded iceberg lettuce, said its bagged lettuce is not associated with the Cyclospora outbreak. Getty Images The lawsuit alleges the couple consumed lettuce with fecal contamination.
Both suits are seeking unspecified damages.
Taco Bell declined to discuss the lawsuits. The Post has sought comment about the suits from Taylor Farms. While it’s pulling iceberg lettuce from Mexico, it wrote on social media that its branded salads and kits are not associated with the outbreak.
The lawsuits came as Taco Bell said it was voluntarily removing “potentially impacted lettuce from a supplier in select states.” Taylor Farms said it was recalling iceberg lettuce sourced from Mexico based on information the FDA’s provided.
Some 1,645 lab-confirmed cases of cyclosporiasis have been reported in 34 states since May 1, with Michigan hit the hardest, according to the Centers for Disease Control and Prevention. Along with it and Ohio, the CDC has urged customers to avoid lettuce at Indiana, Kentucky and West Virginia Taco Bells in particular.
At least 141 people have been hospitalized, with no deaths reported, authorities said.
The number of confirmed cases is expected to rise, with the feds saying they are reviewing over 5,100 additional reports to determine whether they are cyclosporiasis.
New York State saw 511 cyclosporiasis cases between May 1 and July 10, according to local health officials.
In the latest trading session, Toyota Motor Corporation (TM - Free Report) closed at $177.61, marking a -1.2% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 1.01%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%.
Heading into today, shares of the company had gained 3.35% over the past month, outpacing the Auto-Tires-Trucks sector's loss of 2.36% and the S&P 500's gain of 0.32%.
The investment community will be closely monitoring the performance of Toyota Motor Corporation in its forthcoming earnings report.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $20.99 per share and revenue of $325.34 billion, indicating changes of +7.04% and -3.29%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Toyota Motor Corporation. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.5% downward. Currently, Toyota Motor Corporation is carrying a Zacks Rank of #5 (Strong Sell).
Looking at valuation, Toyota Motor Corporation is presently trading at a Forward P/E ratio of 8.56. For comparison, its industry has an average Forward P/E of 9.63, which means Toyota Motor Corporation is trading at a discount to the group.
The Automotive - Foreign industry is part of the Auto-Tires-Trucks sector. This group has a Zacks Industry Rank of 193, putting it in the bottom 22% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Obsession and F1 were front and center as lawyers representing Paramount on one side, and a dozen State Attorneys General on the other, clashed at a Friday hearing over what determines a blockbuster, and how quickly the AGs’ antitrust challenge to Paramount’s merger with Warner Bros Discovery should be moved along.
Jeffrey Kessler on behalf of Paramount requested Judge Araceli Martínez-Olguín of the Northern District of California dispense with a temporary restraining order and promised Par would not close the deal early if she promised to rule on a preliminary injunction by the beginning of September. That timetable could potentially avert “very severe harm” to Paramount from a so-called ticking fee – addition payouts by Paramount to WBD shareholders staring October 1 if the deal has not been finalized.
The AGs attorney James Weingarten called it “unprecedented and unfair” for Par to propose a timeline “in order to help them save a payment that they agreed to make.”
The AGs led by California’s Rob Bonta are seeking a TRO or preliminary injunction. Judge Martínez-Olguín said at the close of the hearing in an Oakland County courtroom that she would issue a written ruling before July 22. That’s the date of an anticipated greenlight by EU antitrust authorities and the earliest the merger could theoretically close.
The AGs’ suit focused on three markets – blockbuster films, wide release movies, and cable networks — where it claims the combined company’s large share would undermine competition and harm consumers, making the deal illegal under antitrust law.
The AGs argue a blockbuster is something only the five biggest Hollywood studios have the financial chops to produce, market and distribute on a regular basis. Going from five to four majors would clearly disadvantage theater owners, who depend on those films, and ultimately lead to higher ticket prices for consumers, Weingarten said.
Kessler reiterated Paramount’s argument that the entertainment industry is changing and it makes no sense to look just at the share of the big five. He noted the massive box office for YouTube star Curry Barker’s Obsession, made for $750,000, which has grossed close to $430 million worldwide, calling that a “real world fact” and “undisputed economic evidence” that times have changed.
Weingarten dismissed the Obsession argument as irrelevant. “I’m not saying no one can have a super hit or a breakout, but there are five majors that make blockbusters consistently.”
Obsession was released by Focus Features, the independent film arm of Universal Studios.
Paramount also noted competition from A24, Neon and streamers who have entered the theatrical space. “We had Amazon do F1 last year, which was a dramatic success,” Kessler said, before correcting himself to note that it was an Apple film. “So Apple does not exist as a competitor even though they have shown in the real world that they have done that, and will probably continue to do that?” he asked.
Weingarten gleefully shot back that Apple had indeed made a “successful big movie, but it was distributed by Warner Bros.”
“Apple makes cell phones, not movies,” he said.
Amazon has committed to release 15 films a year theatrically, Kessler noted.
On the ticking fee, the Ellisons, Paramount’s controlling shareholders, agreed to pay 25 cents cash per share per quarter (about $7.2 million a day, or $650 million every three months) for each day the merger is not closed starting October 1. It was a sweetener to convince WBD’s board of directors to accept their $110 billion offer.
But that’s no reason “to short circuit the process in an unprecedented way,” Weingarten insisted. “You need to hear from competitors and customers. Those are the people that tell the court what really goes on in the marketplace, so we need a reasonable schedule” in keeping with other cases of such magnitude. He noted that Paramount itself has called the merger “industry transforming.”
“I don’t know when in August we are supposed to talk to all those people … The orderly course is a TRO. Having two experts in a food fight in a month will just waste everybody’s time.”
Kessler shot back that the lawsuit led by California state Attorney General Rob Bonta could have been filed “a month ago, or six weeks ago,” so it’s the plaintiffs who “created the emergency.”
In the latest trading session, NetApp (NTAP - Free Report) closed at $163.88, marking a +2.62% move from the previous day. The stock's change was more than the S&P 500's daily loss of 1.01%. At the same time, the Dow lost 0.77%, and the tech-heavy Nasdaq lost 1.4%.
The stock of data storage company has fallen by 0.01% in the past month, leading the Computer and Technology sector's loss of 3.73% and undershooting the S&P 500's gain of 0.32%.
The upcoming earnings release of NetApp will be of great interest to investors. The company's upcoming EPS is projected at $2.11, signifying a 36.13% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $1.83 billion, reflecting a 17.43% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $8.88 per share and a revenue of $7.48 billion, representing changes of +9.23% and +8.07%, respectively, from the prior year.
Any recent changes to analyst estimates for NetApp should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Currently, NetApp is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, NetApp is currently trading at a Forward P/E ratio of 17.99. This expresses a premium compared to the average Forward P/E of 14.84 of its industry.
One should further note that NTAP currently holds a PEG ratio of 2.35. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Computer- Storage Devices was holding an average PEG ratio of 1.53 at yesterday's closing price.
The Computer- Storage Devices industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 22, putting it in the top 9% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
In the latest trading session, Carvana (CVNA - Free Report) closed at $67.34, marking a -4.7% move from the previous day. The stock's change was less than the S&P 500's daily loss of 1.01%. Elsewhere, the Dow saw a downswing of 0.77%, while the tech-heavy Nasdaq depreciated by 1.4%.
Heading into today, shares of the company had gained 6.16% over the past month, outpacing the Retail-Wholesale sector's gain of 0.78% and the S&P 500's gain of 0.32%.
The investment community will be paying close attention to the earnings performance of Carvana in its upcoming release. The company is slated to reveal its earnings on July 29, 2026. In that report, analysts expect Carvana to post earnings of $0.42 per share. This would mark year-over-year growth of 61.54%. Meanwhile, our latest consensus estimate is calling for revenue of $6.96 billion, up 43.8% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.58 per share and a revenue of $28.29 billion, indicating changes of -6.51% and +39.19%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Carvana. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.19% higher within the past month. Carvana is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Carvana has a Forward P/E ratio of 44.64 right now. This indicates a premium in contrast to its industry's Forward P/E of 17.3.
We can also see that CVNA currently has a PEG ratio of 11.9. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Internet - Commerce was holding an average PEG ratio of 1.1 at yesterday's closing price.
The Internet - Commerce industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 170, which puts it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Agentic AI could lead to major breakthroughs in productivity and drive the next wave of growth for many companies. Grand View Research forecasts that the enterprise agentic AI market will maintain a 46.2% compound annual growth rate through 2030, reflecting the technology's vast potential.
Two companies are uniquely positioned to capitalize on this opportunity. UiPath (PATH +1.00%) and ServiceNow (NOW 0.59%) both have tools that let companies create and manage AI agents, and both have solid foundations of growing annual recurring revenues.
While both companies have similar opportunities in front of them, if you want to choose just one of them to invest in, here are a few details to consider.
Image source: Getty Images.
ServiceNow has higher annual recurring revenue growth rates Annual recurring revenue is a critical metric for both companies. It indicates baseline growth and suggests how growth may change in the future.
Today's Change
(
-0.59
%) $
-0.61
Current Price
$
103.40
ServiceNow is the larger company and is also growing faster. The company has $12.64 billion in current remaining performance obligations compared to UiPath's $1.9 billion in annual recurring revenue at the end of its fiscal 2027 first quarter.
ServiceNow is also growing its recurring revenue stream faster. It achieved a 22% year-over-year growth rate for subscription revenue in the first quarter. UiPath only managed a 12% year-over-year growth rate for its subscriptions, but its overall revenue was up by 17%.
Almost 9,000 global customers trust ServiceNow, and that includes 85% of the Fortune 500. Those businesses have more financial flexibility to pay more for ServiceNow plans in the future. UiPath has over 10,000 customers, but ServiceNow can charge a premium for its platform.
For instance, ServiceNow has 630 customers that are spending more than $5 million per year with it, while UiPath only has 374 customers paying more than $1 million per year for its platform.
UiPath has a better shot at boosting margins and improving its valuation Although ServiceNow has a higher revenue growth rate, UiPath is well positioned to boost its margins. When discussing UiPath's fiscal 2027 first-quarter results, CFO Ashim Gupta noted that it was the first time the company had achieved GAAP profitability in a Q1.
Today's Change
(
1.00
%) $
0.12
Current Price
$
12.15
UiPath is now in a position to continue scaling without soaring operating expenses. While costs should continue to rise over time, the company's revenue growth could outpace spending growth in future quarters.
ServiceNow has been profitable for much longer and commands double-digit net profit margins. In its latest quarter, UiPath had a net profit margin just above 5%.
UiPath would have to more than double its profit margin to reach ServiceNow's level. Since these agentic AI platforms have similar client lists and serve similar markets, it is feasible for UiPath to achieve that net profit margin in the future.
ServiceNow has still been growing its top line, but its net income growth has been a bit disappointing in recent quarters. Lower net income growth limits how much more attractive ServiceNow's price-to-earnings (P/E) ratio can become, while UiPath is better positioned to improve its valuation.
The final verdict ServiceNow is growing revenues faster and has customers who are willing to pay more for its offerings. However, UiPath recently hit a profitability milestone and is in a good position to expand its margins. Both companies trade at similar P/E ratios, but UiPath has a better shot at making its valuation more attractive for long-term investors.
If ServiceNow can raise prices higher and get some of its costs under control, it can return to delivering double-digit, year-over-year net income growth. If that happens, the thesis will change significantly and favor ServiceNow.
Investors who are more focused on value may want to take a closer look at UiPath, but both companies are well positioned for the upcoming agentic AI boom.
UiPath (PATH +1.00%), an enterprise automation and robotic software provider, closed at $12.15, up 1.00%. The gains follow a recent retail artificial intelligence (AI) partnership, while broader technology weakness stayed in focus.
Trading volume reached 90.6 million shares, coming in about 86% above its three-month average of 48.7 million shares. UiPath IPO'd in 2021 and has fallen 81% since going public.
How the markets moved todayThe S&P 500 (^GSPC 1.01%) fell 1.01% to 7,458, and the Nasdaq Composite (^IXIC 1.40%) fell 1.40% to 25,520. Among robotic process automation rivals, Appian (APPN 0.42%) closed at $26.11, down 0.38%, while Pegasystems (PEGA 2.31%), which will report Q2 earnings next week, closed at $32.16, down 2.31%.
What this means for investorsUiPath erased some of its losses today, but the stock is still down over 26% year-to-date. It automates common back-office business tasks with AI and robotic technology, but it has struggled alongside other software stocks as investors fear that AI might replace its services altogether.
While the firm’s Q1 revenues increased by 17% year-on-year to $418 million, analysts wanted to see stronger subscription figures to demonstrate sustainable prospective growth. As such, its recent deal with UK online retailer The Very Group, under which UiPath will provide agentic AI pricing solutions, could boost its long-term potential.
The deal is positive, but it is only one step in the right direction. UiPath needs to show it can use AI to deliver the services companies need rather than being replaced by this rapidly evolving technology.
Emma Newbery has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends UiPath. The Motley Fool recommends Appian. The Motley Fool has a disclosure policy.
ConocoPhillips (COP - Free Report) closed the most recent trading day at $114.71, moving +1.66% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 1.01% for the day. At the same time, the Dow lost 0.77%, and the tech-heavy Nasdaq lost 1.4%.
Heading into today, shares of the energy company had gained 4.73% over the past month, outpacing the Oils-Energy sector's gain of 1.22% and the S&P 500's gain of 0.32%.
The investment community will be closely monitoring the performance of ConocoPhillips in its forthcoming earnings report. The company is scheduled to release its earnings on August 6, 2026. The company is forecasted to report an EPS of $2.96, showcasing a 108.45% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $17.59 billion, up 19.36% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $9.2 per share and revenue of $66.91 billion, indicating changes of +49.35% and +8.72%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for ConocoPhillips. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 8.28% decrease. Currently, ConocoPhillips is carrying a Zacks Rank of #3 (Hold).
In the context of valuation, ConocoPhillips is at present trading with a Forward P/E ratio of 12.26. This signifies a discount in comparison to the average Forward P/E of 19.72 for its industry.
We can also see that COP currently has a PEG ratio of 1.36. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Oil and Gas - Integrated - United States industry stood at 1.92 at the close of the market yesterday.
The Oil and Gas - Integrated - United States industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 204, which puts it in the bottom 18% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Groupon (GRPN - Free Report) closed the most recent trading day at $27.83, moving -2.62% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 1.01% for the day. Elsewhere, the Dow lost 0.77%, while the tech-heavy Nasdaq lost 1.4%.
Shares of the online daily deal service witnessed a gain of 76.53% over the previous month, beating the performance of the Retail-Wholesale sector with its gain of 0.78%, and the S&P 500's gain of 0.32%.
The upcoming earnings release of Groupon will be of great interest to investors. The company is forecasted to report an EPS of -$0.07, showcasing a 115.22% downward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $127.42 million, up 1.37% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.16 per share and a revenue of $519.48 million, representing changes of +92.23% and +4.23%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Groupon. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 23.68% decrease. Groupon is holding a Zacks Rank of #3 (Hold) right now.
The Internet - Commerce industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 170, which puts it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Capital One on Thursday released VulnHunter, an open-source, agentic AI security tool that scans source code for exploitable vulnerabilities, maps out how an attacker would reach them, and proposes targeted fixes — all before a single line ships to production. The tool, built internally and now available on GitHub under an Apache 2.0 license, is one of the most ambitious attempts by a major financial institution to turn offensive AI capabilities into a public defensive resource.
New York, New York--(Newsfile Corp. - July 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of purchasers of securities of Hub Group, Inc. (NASDAQ: HUBG) between April 28, 2023 and May 11, 2026, inclusive (the "Class Period"), of the important August 28, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Hub Group securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that Hub Group's financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements-caused by the premature and incorrect recognition of certain transactions-concerning, inter alia, Hub Group's operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth. In addition, Hub Group's financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements-caused by the understatement of purchased transportation costs and accounts payable -concerning, inter alia, Hub Group's operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305664
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in PicS N.V. ("PicS" or the "Company") (NASDAQ: PICS) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of PicS who were adversely affected if they purchased the Company's Class A common stock in and/or traceable to its January 30, 2026 initial public offering (the "IPO"). This action is pending in the United States District Court for the Southern District of New York.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=FQIEqld_vCU
Follow the link below to get more information and be contacted by a member of our team:
https://www.ksfcounsel.com/cases/nasdaqgs-pics/
PicS investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-ses/?prs=nf to learn more.
CASE DETAILS: According to the Complaint, PicS and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) in December 2025, the Company determined that its credit assessment procedures were deficient and required enhancement; (ii) following implementation of revised procedures, the Company reclassified approximately R$590 million of exposures from Stage 2 to Stage 3, resulting in an incremental ECL charge of R$88 million for the quarter ended December 31, 2025; (iii) the Company experienced an undisclosed Stage 3 formation rate exceeding 7% in the fourth quarter of 2025, materially departing from the historical trends disclosed in the offering documents; (iv) the offering documents materially overstated the effectiveness of PicS N.V.'s credit models, user data, and underwriting and risk-monitoring capabilities; and (v) prior to the IPO, PicS N.V.'s expansion into riskier business lines had led to deteriorating credit quality, increased default and impairment risk, and adverse financial and operational trends that were expected to continue worsening and materially impact the Company's business and financial results.
The case is FirstFire Global Opportunities Fund, LLC v. PicS N.V., No. 26-cv-04793.
WHAT TO DO? If you invested in PicS and suffered a loss during the relevant time frame, you have until August 4, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner [email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163
ORLANDO, Fla.--(BUSINESS WIRE)--Hilton Grand Vacations Inc. (NYSE:HGV) announces today the successful refinance of its existing $849 million Term Loan B (“TLB”) due 2028 with an amended $850 million TLB due 2033. The TLB pricing remained unchanged at SOFR plus 200. “This successful Term Loan B transaction reflects the strength of our capital markets platform and the confidence investors have in the company's strategy and long-term growth outlook,” said Dan Mathewes, president and chief financia.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Bloom Energy Corporation (“Bloom” or the “Company”) (NYSE: BE) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON BLOOM ENERGY CORPORATION (BE), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On July 8, 2026, Hunterbrook published a report alleging, among other things, that despite the Company repeatedly claiming Bloom has “no China supply chain” and is “not dependent on China for scandium,” (the rare earth at the core of each Bloom fuel cell) “Bloom is, in fact, reliant on C5 Chinese scandium, according to global trade data, Chinese corporate filings, satellite imagery, and Hunterbrook’s messages with Bloom’s suppliers in China.”
On this news, Bloom’s stock price fell $15.28, or 5.7%, to close at $254.29 per share on July 8, 2026, thereby injuring investors.
Contact Us to Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Bloom should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Fifth Third Bancorp (FITB) Q2 2026 Earnings Call July 17, 2026 9:00 AM EDT
Company Participants
Matt Curoe - Senior Director of Investor Relations
Timothy Spence - Chairman, CEO & President
Bryan Preston - Executive VP & CFO
Conference Call Participants
Ebrahim Poonawala - BofA Securities, Research Division
Manan Gosalia - Morgan Stanley, Research Division
Ryan Nash - Goldman Sachs Group, Inc., Research Division
L. Erika Penala - UBS Investment Bank, Research Division
Gerard Cassidy - RBC Capital Markets, Research Division
Michael Mayo - Wells Fargo Securities, LLC, Research Division
John Pancari - Evercore ISI Institutional Equities, Research Division
Brian Foran - Truist Securities, Inc., Research Division
Benjamin Gerlinger - Citigroup Inc., Research Division
Kenneth Usdin - Bernstein Autonomous LLP
Christopher McGratty - Keefe, Bruyette, & Woods, Inc., Research Division
Presentation
Operator
Hello, everyone. Thank you for joining us, and welcome to the Fifth Third's Second Quarter Earnings Call. [Operator Instructions]
I will now hand the conference over to Matt Curoe, Director of Investor Relations. Please go ahead.
Matt Curoe
Senior Director of Investor Relations
Good morning, everyone. Welcome to Fifth Third's Second Quarter 2026 Earnings Call. This morning, our Chairman, CEO and President, Tim Spence; and CFO, Bryan Preston, will provide an overview of our second quarter results and outlook.
Please review the cautionary statements in our materials, which can be found in our earnings release and presentation. These materials contain information regarding the use of non-GAAP measures and reconciliations to the GAAP results as well as forward-looking statements about Fifth Third's performance. These statements speak only as of July 17, 2026, and Fifth Third undertakes no obligation to update them. Following prepared remarks by Tim and Bryan, we will open up the call for questions.
With that, let me turn it over to Tim.
Timothy Spence
Chairman, CEO & President
Good morning, everyone, and thank you for joining us. At Fifth
HOUSTON--(BUSINESS WIRE)--Comfort Systems USA, Inc. (NYSE: FIX), a leading provider of mechanical and electrical contracting services including heating, ventilation, air conditioning, plumbing, electrical, piping and controls, announces that it has scheduled its quarterly conference call and webcast for Friday, July 24, 2026, at 10:00 a.m. Central Time to discuss second quarter 2026 financial results. The results will be released after the market closes on Thursday, July 23, 2026.
The conference call will be webcast live in listen-only mode on the Company’s website at https://investors.comfortsystemsusa.com/. The call and the slide presentation to accompany the remarks can be accessed under the “Investors” tab after second quarter 2026 results are released. Participants who want to join the call and ask a question may register at https://register-conf.media-server.com/register/BI777a987fe0b945e9888811125e5fa190 to receive the dial-in information and a unique PIN to seamlessly access the call. Otherwise, please access the listen-only webcast link.
On the next business day following the call, a replay of the entire call will be available on the Company’s website.
Comfort Systems USA® is a premier provider of business solutions addressing workplace comfort, with 206 locations in 150 cities around the nation. For more information, visit the Company’s website at www.comfortsystemsusa.com.
Advance Auto Parts urges drivers across the Northeast and Midwest to check their cabin air filters as air quality worsens across the region
, /PRNewswire/ -- Wildfire smoke is choking the Northeast and Midwest. Residents are sealing windows, running air purifiers, and checking home air filters. And while their cars already have built-in protection, few know it – and even fewer maintain it.
According to national data1 released earlier this year by Advance Auto Parts, Inc. (NYSE: AAP), half of American drivers don't realize their vehicle has a cabin air filter at all. Another 54% have never replaced theirs.
The Filter You're Ignoring Right Now
Your cabin air filter traps smoke particles, pollen and other pollutants before they enter your cabin through the HVAC system. When wildfires rage and air quality plummets, a clean filter is the difference between breathing protected air or smoke-filled air during your commute. When neglected, filters clog and smoke gets through.
The Numbers Drivers Should Know
The data reveals a glaring gap in how people protect themselves on the road:
71% of allergy sufferers swap out their home air filters every 90 days, but only 51% have ever replaced a car cabin filter 68% of drivers care about air quality inside their vehicles but don't act on it 55% of drivers spend 4+ hours weekly in their cars What to Do This Week
Locate your filter. Check your owner's manual. It's usually behind the glove box or under the hood. Your manual shows exactly how to access it safely. Inspect it. Hold it up to light. If it looks gray, brown, or visibly clogged with dust, it needs replacing today. Clean filters appear relatively white or light-colored. Replace on schedule. Most cabin air filters need changing every 12,000 to 15,000 miles or at least once per year, depending on driving conditions and air quality. Use recirculation mode. During heavy smoke days, activate your vehicle's recirculation setting to block outside air and maximize filter protection. Advance Auto Parts stocks cabin air filters for every make and model. Visit AdvanceAutoParts.com or your local store to find the right cabin air filter for your vehicle.
Atomik Research1
About Advance Auto Parts:
Advance Auto Parts, Inc. is a leading automotive aftermarket parts provider that serves both professional installer and do-it-yourself customers. As of April 25, 2026, Advance operated 4,308 stores primarily within the United States, with additional locations in Canada, Puerto Rico and the U.S. Virgin Islands. The Company also served 797 independently owned Carquest branded stores across these locations in addition to Mexico and various Caribbean islands. Additional information about Advance, including employment opportunities, customer services, and online shopping for parts, accessories and other offerings can be found at www.AdvanceAutoParts.com.
1 Atomik Research surveyed 1,000 adult vehicle owners and operators, 50% of whom manage seasonal allergies in their households. Margin of error: +/- 3 percentage points at 95% confidence level.
KLAC weekly chart shows decline into rising channel formation following peak. Source: TradingView Given the decisive bearish response that followed the peak, it appears a key resistance level was reached. The high coincided with a 150% extension of a rising trend channel. Shortly after reaching that high, KLAC fell back into the channel formation and found support near the channel’s midline. This is the second time in recent weeks that buyers and sellers have recognized the channel’s structure, reinforcing its technical significance. This week, however, last week’s low of $210.86 was broken, confirming a decline below the channel midline.
Weekly Chart Points to Lower Support Moreover, this week ended at $212.17, below the midline, further confirming downward pressure. Once the midline fails as support, the lower channel boundary becomes a potential target. At a minimum, this suggests further downside is likely during the current correction. Based on the weekly chart, the next lower target zone is near the prior trend high of $193.94 and the rising 20-week moving average, currently at $191.23.
SAN JOSÉ, Calif.--(BUSINESS WIRE)--Power Integrations (Nasdaq: POWI) today announced that on July 15, 2026 (the Grant Date), it granted a total of 12,017 RSUs and 1,213 PSUs at target to five employees who began their employment with Power Integrations in June 2026.
The inducement grants were issued pursuant to Power Integrations’ Amended and Restated 2025 Inducement Award Plan. One-fourth (1/4th) of the RSUs will vest on each of the first four anniversaries of the Grant Date, subject to the recipient’s continued service through each applicable vesting date. The PSUs will vest based upon achievement of the Company’s performance metrics for 2026, as determined by the Talent and Compensation Committee of the Company’s Board of Directors, up to a maximum of 200% of the target number of PSUs, subject to continued service through December 31, 2026. The inducement grants are subject to the terms and conditions of the applicable RSU and PSU agreements and Power Integrations’ Amended and Restated 2025 Inducement Award Plan.
The inducement grants were approved by the Talent and Compensation Committee of Power Integrations’ Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).
About Power Integrations
Power Integrations, Inc. is a leading innovator in semiconductor technologies for high-voltage power conversion. The company’s products are key building blocks in the clean-power ecosystem, enabling the generation of renewable energy as well as the efficient transmission and consumption of power in applications ranging from milliwatts to megawatts. For more information please visit www.power.com.
Power Integrations and the Power Integrations logo are trademarks or registered trademarks of Power Integrations, Inc. All other trademarks are property of their respective owners.
, /PRNewswire/ -- The J.M. Smucker Co. (NYSE: SJM) today announced its Board of Directors approved an increase in the quarterly dividend from $1.10 to $1.12 per common share, an increase of two percent. The next dividend will be paid on Tuesday, September 1, 2026, to shareholders of record at the close of business on Friday, August 14, 2026. This increase marks the Company's 25th consecutive fiscal year of dividend growth, reflecting the Company's continued commitment to returning value to shareholders.
The J.M. Smucker Co. Forward-Looking Statement
This press release contains a forward-looking statement about dividends. This statement is made on the basis of the Company's views and assumptions as of this time, and the Company undertakes no obligation to update this statement unless required by law. This statement is not a guarantee of future performance, and actual events or results may differ materially from this statement. Investors should consult the Company's filings with the Securities and Exchange Commission (including the information set forth under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2026) for information about certain factors that could cause such differences. Copies of these filings may be obtained by visiting the Company's website at jmsmucker.com.
About The J.M. Smucker Co.
At The J.M. Smucker Co., it is our privilege to make food people and pets love by offering a diverse family of brands available across North America. We are proud to lead in the coffee, peanut butter, fruit spreads, frozen handheld, sweet baked goods, dog snacks, and cat food categories by offering brands consumers trust for themselves and their families each day, including Folgers®, Dunkin'®, Café Bustelo®, Jif®, Uncrustables®, Smucker's®, Hostess®, Milk-Bone®, and Meow Mix®. Through our unwavering commitment to producing quality products, operating responsibly and ethically and delivering on our Purpose, we will continue to grow our business while making a positive impact on society. For more information, please visit jmsmucker.com.
The J.M. Smucker Co. is the owner of all trademarks referenced herein, except for Dunkin'®, which is a trademark of DD IP Holder LLC. The Dunkin'® brand is licensed to The J.M. Smucker Co. for packaged coffee products sold in retail channels, such as grocery stores, mass merchandisers, club stores, e-commerce and drug stores, and in certain away from home channels. This information does not pertain to products for sale in Dunkin'® restaurants.
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Delek US Holdings, Inc. (NYSE: DK) (“Delek US”) today announced that the Company intends to issue a press release summarizing second quarter 2026 results before the U.S. stock market opens on Wednesday, August 5, 2026. A conference call to discuss these results is scheduled to begin at 10:00 a.m. CT (11:00 a.m. ET) on Wednesday, August 5, 2026.
The live broadcast of this conference call will be available online by going to www.DelekUS.com and clicking on the investor relations section of the website. A presentation containing supplemental financial information will also be available online at ir.delekus.com prior to the conference call and webcast. The Company does not intend to furnish this presentation on a Current Report on Form 8-K. Investors are encouraged to review the presentation in conjunction with the Company’s earnings press release and webcast. The online replay will be available on the website for 90 days.
About Delek US Holdings, Inc.
Delek US Holdings, Inc. is a diversified downstream energy company with assets in petroleum refining, logistics, pipelines, and renewable fuels. The refining assets consist primarily of refineries operated in Tyler and Big Spring, Texas, El Dorado, Arkansas and Krotz Springs, Louisiana with a combined nameplate crude throughput capacity of 302,000 barrels per day.
The logistics operations include Delek Logistics Partners, LP (NYSE: DKL). Delek Logistics Partners, LP is a growth-oriented master limited partnership focused on owning and operating midstream energy infrastructure assets. Delek US Holdings, Inc. and its subsidiaries owned approximately 63.3% (including the general partner interest) of Delek Logistics Partners, LP as of June 30, 2026.
Information about Delek US Holdings, Inc. can be found on its website (www.delekus.com), investor relations webpage (ir.delekus.com), and news webpage (www.delekus.com/news).
NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action in the U.S. District Court for the District of Delaware alleging violations of the federal securities laws by AeroVironment, Inc. (“AeroVironment” or the “Company”) and certain of the Company’s current senior executives (collectively, “Defendants”). The action is brought on behalf of all investors who purchased or otherwise acquired AeroVironment common stock beginning at 4:30 PM ET on June 24, 2025, through June 18, 2026, inclusive (the “Class Period”). This case is related to a previously filed securities class action pending against AeroVironment captioned Norrell v. AeroVironment, Inc., No. 1:26-cv-1429 (E.D. Va. filed May 26, 2026) (“Norrell”).
BLB&G filed this action on behalf of its client, City Pension Fund for Firefighters and Police Officers in the City of Miami Beach, and the case is captioned City Pension Fund for Firefighters and Police Officers in the City of Miami Beach v. AeroVironment, Inc., No. 26-cv-00875 (D. Del.). The complaint is based on an extensive investigation and a careful evaluation of the merits of this case. A copy of the complaint is available on BLB&G’s website by clicking here.
AeroVironment’s Alleged Fraud
AeroVironment is a defense technology provider across air, land, sea, space, and cyber. Shortly before the Class Period, AeroVironment acquired BlueHalo, LLC (“BlueHalo”), another defense technology company with a leading role in the U.S. Department of Defense’s (“DoD”) Satellite Communications Augmentation Resource (“SCAR”) program. Through SCAR, BlueHalo had been awarded a contract valued at approximately $1.7 billion to develop military satellite command and control stations known as Broad Area Deployable Ground Terminal Enabling Resilient Communications (“BADGERs”).
The claims against AeroVironment and certain of its executives arise from misrepresentations relating to the SCAR contract. Throughout the Class Period, Defendants repeatedly touted the SCAR program as central to AeroVironment’s growth prospects. Defendants told investors that the Company had “won” the SCAR contract, that it was “locked in,” that the customer was “asking for more,” and that the Company was “very much on track” to ramp revenue and improve margins as more BADGER systems moved into production. In truth, AeroVironment’s agreement with the U.S. DoD to produce BADGERs for the SCAR program was not secure, as AeroVironment was facing a significant threat of competition from other vendors for the work it was performing under that agreement, and there was a material risk that the Company would not continue to deliver products for the SCAR program, or would do so only on a significantly reduced basis.
The truth began to emerge on January 20, 2026, when AeroVironment announced that the U.S. Government had issued a stop work order on the SCAR contract. As a result of this disclosure, the price of AeroVironment common stock declined by $61.97 per share, or 16%. Then, on March 2, 2026, industry publication Space News reported that the U.S. DoD was reopening the SCAR program and soliciting proposals from vendors other than AeroVironment because the Space Force was “reassessing how to move forward.” That news caused the price of AeroVironment common stock to decline by $43.93 per share, or 17%.
On March 10, 2026, AeroVironment revealed that the U.S. Government intended to terminate the SCAR agreement, while allowing AeroVironment to compete for future work under the program. The Company also reported a $151.3 million goodwill impairment charge in the Space reporting unit triggered by the SCAR stop work order. These disclosures caused the price of AeroVironment common stock to decline by $13.84 per share, or 6%. Then, on June 22, 2026, AeroVironment disclosed that its previously issued financial statements should no longer be relied upon because the Company had understated the goodwill impairment charge by $89.4 million, or 59%. AeroVironment further disclosed that the restatement resulted from a newly identified material weakness in internal control over financial reporting and that its disclosure controls and procedures as of January 31, 2026, were ineffective. As a result of these disclosures, the price of AeroVironment common stock declined by $18.28 per share, or 11%.
The filing of this action does not alter the previously established deadline to seek appointment as Lead Plaintiff. Pursuant to the May 27, 2026, notice published in connection with the Norrell action, under the Private Securities Litigation Reform Act of 1995, investors who purchased AeroVironment common stock during the Class Period may, no later than July 27, 2026, seek to be appointed as Lead Plaintiff for the Class. Any member of the proposed Class may seek to serve as Lead Plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed Class.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Scott R. Foglietta of BLB&G at 212-554-1903, or via e-mail at [email protected].
About BLB&G
BLB&G is widely recognized worldwide as a leading law firm advising institutional investors on issues related to corporate governance, shareholder rights, and securities litigation. Since its founding in 1983, BLB&G has built an international reputation for excellence and integrity and pioneered the use of the litigation process to achieve precedent-setting governance reforms. Unique among its peers, BLB&G has obtained several of the largest and most significant securities recoveries in history, recovering over $40 billion on behalf of defrauded investors. More information about the firm can be found online at www.blbglaw.com.
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in AeroVironment, Inc. ("AeroVironment" or the "Company") (NASDAQ: AVAV) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of AeroVironment, Inc. who were adversely affected if they purchased the Company's securities between June 25, 2025 and March 10, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for the Eastern District of Virginia.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=b86qi_eJ54U
Follow the link below to get more information and be contacted by a member of our team:
https://www.ksfcounsel.com/cases/nasdaqgs-avav/
AeroVironment investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-avav/ to learn more.
CLICK HERE for more information
CASE DETAILS: According to the Complaint, AeroVironment and certain of its executives are charged with failing to disclose material information during the class period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the U.S. Space Force's Satellite Communication Augmentation Resource program and the U.S. Space Force's ongoing efforts to modernize the Satellite Control Network; (ii) accordingly, defendants overstated AeroVironment's business and financial prospects; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.
The case is Norrell v. AeroVironment, Inc., et al, No. 26-cv-01429.
WHAT TO DO? If you invested in AeroVironment and suffered a loss during the relevant time frame, you have until July 27, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.
To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
If you purchased or acquired AeroVironment securities between June 25, 2025 and June 18, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected], or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) --
What’s Happening?
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Aerovironment, Inc. (“Aerovironment” or the “Company”) (NASDAQ:AVAV) in the United States District Court for the Eastern District of Virginia on behalf of all persons and entities who purchased or otherwise acquired AeroVironment securities between June 25, 2025 and June 18, 2026, both dates inclusive (the “Class Period”).Investors have until July 27, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details?
The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts by understating the likelihood that AeroVironment would imminently face competition from other vendors for the work it performed in connection with the Satellite Communication Augmentation Resource program and the U.S. Space Force’s ongoing efforts to modernize the Satellite Control Network.On January 20, 2026, AeroVironment announced that the U.S. government had issued a stop work order on the Company’s agreement to deliver BADGER systems to the SCAR program. On this news, AeroVironment's stock price fell $61.97 per share, or over 15%, to close at $330.89 per share on January 20, 2026.Then, on March 10, 2026, AeroVironment announced disappointing financial results for the third quarter of fiscal year 2026. These financial results reflected the impact of a $151.3 million goodwill impairment in the Company’s space division after the stop work order on the Company’s BADGER systems built for the SCAR program. AeroVironment also reported that the U.S. Space Force had terminated the Company’s contract concerning the SCAR program, and as a result, it would have to “recompete” for the SCAR program. On this news, AeroVironment’s stock price fell $13.84 per share, or 6.24%, to close at $207.73 per share on March 11, 2026. What are my Next Steps?
If you purchased or otherwise acquired Aerovironment shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
New York, New York--(Newsfile Corp. - July 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 25, 2025 and March 10, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.
SO WHAT: If you purchased AeroVironment securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the AeroVironment class action, go to https://rosenlegal.com/cases/aerovironment-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the U.S. Space Force's Satellite Communication Augmentation Resources ("SCAR") program and the U.S. Space Force's ongoing efforts to modernize the Satellite Control Network ("SCN"); (2) accordingly, defendants overstated AeroVironment's business and financial prospects; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the AeroVironment class action, go to https://rosenlegal.com/cases/aerovironment-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305659
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ZoomInfo Technologies Inc. ("ZoomInfo" or the "Company") (NASDAQ: GTM) on behalf of investors that purchased or otherwise acquired ZoomInfo securities between November 3, 2025 and May 11, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in ZoomInfo and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 24, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On May 11, 2026, after the market closed, ZoomInfo reported its first quarter 2026 financial results. The Company reduced its 2026 revenue guidance from a range of $1.247 - $1.267 billion to $1.185 - $1.205 billion. During the subsequent earnings call, Chief Executive Officer Henry Schuck stated that "[i]n the closing days of March and into April, [the Company] saw a trend of AI and agentic confusion," which led to "a pause in purchasing decisions." According to the complaint, the Company also announced restructuring costs of $45 million to $60 million and that it would be laying off 20% of its workforce.
Following this news, on May 12, 2026, the price of ZoomInfo stock fell $1.98 per share, nearly 33%, to close at $4.06 per share.
The complaint alleges that throughout the Class Period Defendants created the false impression that they possessed reliable information pertaining to the Company's projected revenue outlook and anticipated growth of its legacy and emerging AI-driven products, core software business and sustained improvement in net revenue retention. Further, the complaint alleges that, in truth, ZoomInfo's optimistic plan for continued growth was undermined by slowing seat-based demand, weakening upsells and customers revising decisions to purchase AI products and develop internal AI-driven go-to-market solutions, making ZoomInfo's 2026 full year revenue guidance increasingly unlikely to be met.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
On June 2, 2026, the Federal Drug Administration ("FDA") published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" The FDA further states that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."
Following this news, the price of Medline stock fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026.
According to a June 3, 2026 Reuters article, the latest FDA warning letter relates to "violations of manufacturing quality standards" and is "the second such action against the [C]ompany in two months." Further, the Reuters article states that according to the FDA, "the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this investigation, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Verra To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Verra between February 24, 2026 and May 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - July 17, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Verra Mobility Corporation ("Verra" or the "Company") (NASDAQ: VRRM) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra's relationship with Avis Budget Group ("Avis"), and in particular obtaining a contract extension with Avis. Further, the Company minimized concerns that major rent-a-cars could replace Verra with in-house solutions or outsourced alternatives.
On May 26, 2026, Verra issued a press release announcing a termination notice from Avis regarding its contract and accordingly lowered its 2026 full-year financial outlook. Almost one week later on June 1, 2026, the Company announced a sudden and surprising transition of its President and Chief Executive Officer David Roberts. Following this news, the price of Verra's common stock declined dramatically.
From a closing market price of $13.08 per share on May 26, 2026, Verra's stock price fell to $3.85 per share on May 27, 2026, a decline of about 71%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Verra's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Verra class action, go to www.faruqilaw.com/VRRM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Verra Mobility Securities Class Action Lawsuit:
What is the Verra Mobility securities fraud lawsuit about?
The lawsuit alleges Verra Mobility misled investors about the strength of its relationship with Avis Budget Group, the likelihood of a contract extension, and the risk that major rental car companies could replace Verra's services with alternative solutions.
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired Verra Mobility (NASDAQ: VRRM) securities between February 24, 2026 and May 26, 2026 may be eligible to participate if they suffered losses related to the alleged misconduct described in the complaint.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff represents the interests of the proposed class and helps oversee the litigation. Investors seeking appointment must file a motion with the court by August 4, 2026. Investors can share in any recovery without serving as lead plaintiff.
What should investors do if they purchased Verra Mobility stock during the Class Period?
Investors should review their transaction records, preserve relevant documents, and evaluate their legal rights. Those who suffered losses may wish to consult counsel regarding participation in the lawsuit or seeking lead plaintiff status before the deadline.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Verra Mobility securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305473
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Verra Mobility Corporation ("Verra Mobility" or the "Company") (NASDAQ: VRRM) on behalf of investors that purchased or otherwise acquired Verra Mobility common stock between February 24, 2026 and May 26, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Verra Mobility and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 4, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On May 26, 2026, Verra Mobility issued a press release disclosing that the Company had received a termination notice from Avis Budget Group regarding its contract, which becomes effective in September 2026. Verra Mobility further disclosed that it "expects the termination to reduce Commercial Services' 2026 annualized revenue by approximately $135 million to $145 million and 2026 annualized segment profit by approximately $120 million to $125 million, before taking into account expected cost reduction initiatives." Verra also lowered its full year 2026 financial outlook.
Following this news, Verra Mobility's stock price fell $9.23 per share, or 70.6%, to close at $3.85 per share on May 27, 2026.
The complaint alleges that throughout the Class Period, Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra Mobility's relationship with Avis Budget Group.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
July 17, 2026 16:15 ET | Source: ZENTALIS PHARMACEUTICALS
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
"We are pleased that the overall survival results from the DENALI Part 1b study are accepted as a rapid oral presentation at ESMO.” said Julie Eastland, Chief Executive Officer. “The data will showcase the long-term survival benefits demonstrated by azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer in this study and further support our strategic focus on advancing azenosertib in registration-intended monotherapy trials for this biomarker-selected patient population with high unmet need.”
Rapid oral presentation:
Title: “Azenosertib in platinum-resistant ovarian cancer (PROC): overall survival analysis from Part 1b of the DENALI study (GOG-3066)”
Date/Time: Friday, October 23, 2026, 4:15 p.m. - 5:45 p.m. CEST
Presentation Number: 1242RO
Trial-in-progress poster presentation:
Title: “ASPENOVA: A phase 3 study of azenosertib monotherapy versus standard of care chemotherapy in cyclin E1-positive platinum-resistant ovarian cancer (PROC)”
Date/Time: Monday, October 26, 2026, 12:00 p.m. - 12:45 p.m. CEST
Presentation Number: 1339TiP
About DENALI Clinical Trial
DENALI is a multi-part Phase 2 registration-intended clinical trial (NCT05128825) studying azenosertib in PROC patients.
Part 1b enrolled patients with PROC regardless of Cyclin E1 protein expression, all treated at 400mg QD 5:2 (5 days once-daily administration of azenosertib, followed by 2 days without azenosertib).
Part 2 is prospectively enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis' proprietary immunohistochemistry cutoff. Part 2, in total, is designed to support accelerated approval, pending positive study outcomes and further discussions with the FDA. The study design consists of the following parts:
Part 2a: Dose confirmation evaluated two doses, 300mg QD 5:2 and 400mg QD 5:2, with approximately 30 patients enrolled per dose group. 400mg QD 5:2 was selected as the optimal monotherapy dose. Recruitment at the 300mg QD 5:2 dose level has been discontinued. All patients enrolled in Part 2a will contribute to the overall safety database submitted to the FDA.Part 2b: Enrollment expansion at the selected 400mg QD 5:2 dose up to approximately 100 patients, including patients at this dose in Part 2a. This cohort is currently enrolling.Part 2c: Broadening study population, which is expected to include approximately 40 patients previously treated with a taxane-containing regimen for PROC. This cohort is currently enrolling. For physician and patient information about the DENALI trial, please visit www.denalitrial.com.
About ASPENOVA Clinical Trial
ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 to investigator's choice of standard-of-care single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin [PLD], gemcitabine, or topotecan) in this biomarker-selected population. The primary endpoint is progression-free survival (PFS); key secondary endpoints include overall survival (OS) and overall response rate (ORR). The trial design was based on feedback from the U.S. FDA regarding requirements for seeking approval under the accelerated approval pathway and requirements to support potential conversion to full approval.
About Azenosertib
Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated in clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.
Azenosertib is in late-stage development as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). There is currently no approved treatment option specifically for this biomarker-selected population which comprises approximately 50% of PROC patients. Cyclin E1 protein overexpression has been established as a sensitive and specific predictive biomarker for identifying patients who could potentially derive benefit from azenosertib treatment.
About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the continued development of azenosertib; the clinical and therapeutic potential of azenosertib; the potential for azenosertib to be first-in-class;; the broad franchise potential of azenosertib; the Company’s biomarker-driven strategy for azenosertib; and our participation in poster presentations. The terms “anticipate,” “advance,” “believe,” “design,” “develop,” “expect,” “intent,” “look forward,” “on track,” “plan,” “position,” “potential,” “runway,” “strategy,” “support,” “target,” “upcoming,” and “will” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of azenosertib; our plans, including the costs thereof, of development of companion diagnostics; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption “Risk Factors” in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
The aisles are packed with the same bulk goods you would find in a California suburb: 50-pound bags of rice, high-end electronics, and automotive supplies. But this isn't California. It's a shopping hub in the Caribbean, and the customers waiting in line are members of PriceSmart (PSMT 1.61%), a company that has exported the U.S. warehouse club model to the emerging markets of Latin America and the Caribbean. Trading at $194.56 as of July 14, 2026, the stock has rallied over 80% over the past year, reflecting investor appetite for its consistent, consumption-based business model despite regional headwinds.
Our proprietary Hidden Gems scoring system assigns PriceSmart an overall Superscore of 79 out of 100, placing it in the Strong category. The Superscore is an AI-powered score that evaluates a company's overall strength by combining financial performance, product market position, technological capabilities, leadership quality, and relative valuation. It represents the unification of all our scores into a single score for public companies, with five rating bands: Exceptional (90-100), Strong (75-89), Above Average (60-74), Average (40-59), and Cautious (0-39).
Image source: Getty Images.
Why PSMT Has a 79 SuperscoreDisciplined expansion: Management has successfully scaled the footprint to 57 clubs as of May 31, 2026, with an active pipeline of new locations in Chile, Costa Rica, and the Caribbean, driving reliable growth in its store count.Pricing power: The company had successfully implemented a $5 membership fee increase in fiscal 2024 without triggering significant churn, confirming that the membership value proposition remains sticky.Recurring revenue: Membership renewal rates have shot up to 90.5% as of the third quarter of 2026, providing a predictable, high-margin revenue base that serves as a critical buffer against the inherent volatility of the retail sector.Operational modernization: Investments in the RELEX supply chain platform and the Elera point-of-sale system are actively removing operational friction, allowing for better inventory management and deeper digital member engagement.Why Is PSMT's Superscore Not Higher?Currency volatility: Operations span diverse economies across Latin America and the Caribbean, meaning foreign exchange shifts often pressure reported margins, even when underlying constant-currency performance remains robust.Valuation premium: The stock trades at a trailing P/E of 37.34, a high multiple that implies significant future growth expectations, potentially leaving little margin for error if expansion velocity slips.Regional dependence: The company is inherently tied to the economic health and political stability of its operating regions, introducing a structural risk profile that is more complex than that of domestic retail peers.Hidden Gems Database Scores at a GlanceScoreScore (out of 100)Supporting Data PointProduct (1Y)83Operational momentum is driven by a 13.7% increase in membership income and the successful rollout of advanced technology stacks like RELEX.Product (5Y)74The company maintained a 9.8% revenue CAGR from 2021 to 2025, demonstrating steady execution in a niche regional market.Financial (1Y)73Fiscal 2025 results featured a 25.9% surge in operating cash flow to $261.3 million, highlighting improved conversion efficiency.Financial (5Y)74Consistent profitability has been underpinned by stable net margins of 2.7% and a low debt-to-equity ratio of 0.26 as of fiscal 2025.Leaders95Management maintains a transparent, long-term capital allocation strategy with a 99.3% shareholder approval rating on compensation policies.AI17The business operates as a traditional retailer without the proprietary datasets required for advanced data-driven competitive advantages.Valuation Risk53The stock carries a trailing P/E of 37.34, which suggests the market has already priced in substantial future growth.Who Should Buy PSMT Stock Now?You should consider investing if...
You are seeking long-term exposure to emerging market growth through established consumer staples stocks that benefit from a sticky, membership-based recurring revenue model.You are comfortable with geographic diversification outside of the U.S. and believe the warehouse club format will continue to gain traction among growing middle-class families in Latin America.You may want to avoid this stock if...
You have a low tolerance for the currency fluctuations and macroeconomic instability that often impact retailers operating in developing regional markets.You prioritize bargain-priced stocks, as the current valuation appears to fully account for the company's expansion roadmap and leaves little room for operational disappointments.The Superscore serves as a data-driven foundation for research, but investors should always weigh this framework against their personal risk tolerance and financial goals before making an investment decision.
Today's Change
(
-1.61
%) $
-3.05
Current Price
$
186.00
My 5-year prediction for PSMT stockPriceSmart’s growth strategy is centered around expanding its warehouse club network across Latin American and the Caribbean. It’s a membership-based retail outlet that benefits from increasing demand among consumers to shop at lower-cost stores.
In addition, PriceSmart has a large number of loyal customers who continue to purchase items at their stores due to lower prices and superior services. In the third quarter, net merchandise sales grew 12.5%, with comparable sales growing 10.7% year over year. Importantly, membership grew at a solid clip of 8.6% to 2.1 million, while renewal rates hit an all-time high of 90.5%. Membership income grew 17.6%, thanks to management rolling out an auto-renewal strategy.
PriceSmart is developing its regional footprint, with Chile set to open its first club in a Santiago mall. Management is investing $100 million for three clubs and supporting offices over the next few years.
Over the next five years, I wouldn’t be surprised if sales continue to grow in the low- to mid-double-digit range. However, management also acknowledged near-term headwinds as selling, general, and administrative (SG&A) costs spike when new clubs come online. Additionally, uncertain trade policies could also weigh on growth.
Overall, PriceSmart remains a solid long-term investment, with momentum firmly on the business’s side.
The Hidden Gems Superscore reflects The Motley Fool's proprietary AI-driven evaluation of a company across product, financial, leadership, and valuation pillars as of the article date and may change over time. Performance figures are point-in-time. Past performance does not guarantee future results.
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Delek Logistics Partners, LP (NYSE: DKL) (“Delek Logistics”) today announced that the Partnership intends to issue a press release summarizing second quarter 2026 results before the U.S. stock market opens on Wednesday, August 5, 2026. A conference call to discuss these results is scheduled to begin at 11:30 a.m. CT (12:30 p.m. ET) on Wednesday, August 5, 2026.
The live broadcast of this conference call will be available online by going to www.DelekLogistics.com and clicking on the webcasts section of the website. The online replay will be available on the website for 90 days.
About Delek Logistics Partners, LP
Delek Logistics is a midstream energy master limited partnership headquartered in Brentwood, Tennessee. Through its owned assets and joint ventures located primarily in and around the Permian Basin, the Delaware Basin and other select areas in the Gulf Coast region, Delek Logistics provides gathering, pipeline, transportation, and other services for its customers in crude oil, intermediates, refined products, natural gas, storage, wholesale marketing, terminalling, water disposal and recycling.
Delek US Holdings, Inc. (NYSE: DK) ("Delek US") owns the general partner interest as well as a majority limited partner interest in Delek Logistics and is also a significant customer.
Information about Delek Logistics Partners, LP can be found on its website (www.deleklogistics.com), investor relations webpage (https://www.deleklogistics.com/investor-relations), and news webpage (https://www.deleklogistics.com/news-releases).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Badger Meter To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Badger Meter between April 18, 2024 and April 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - July 17, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Badger Meter, Inc. ("Badger Meter" or the "Company") (NYSE: BMI) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that Badger Meter's strong financial results reflected "ongoing favorable industry trends," "secular growth drivers," and "solid operating execution." They likewise touted "strong" demand and said they were seeing "robust order pacing and a strong bid pipeline that positions us well for continued sales and earnings growth," and that Badger Meter possessed a "long runway" for growth.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Badger Meter's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Badger Meter class action, go to www.faruqilaw.com/BMI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Badger Meter Securities Class Action Lawsuit:
What is the Badger Meter securities fraud lawsuit about?
The Badger Meter securities fraud lawsuit is a federal securities class action alleging that Badger Meter, Inc. (NYSE: BMI) and its executives made false and misleading statements to investors by touting "strong" demand, a "robust" order pipeline, and a "long runway" for growth while concealing that the Company's financial results were not sustainable. As the truth emerged through a series of disclosures — including disappointing Q2 2025 results and a sequential sales decline forecast on July 22, 2025, missed revenue expectations and a 6% sequential decline in utility water sales on January 28, 2026, and Q1 2026 earnings that missed consensus estimates by $0.26 per share with revenue missing by $28.58 million on April 17, 2026 — BMI's stock price dropped sharply, causing significant losses for investors.
Who may be eligible to participate in the Badger Meter class action lawsuit?
Investors who purchased or acquired Badger Meter (BMI) stock between April 18, 2024 and April 16, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Badger Meter securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Badger Meter employees, and others with relevant information about the Company's conduct are also encouraged to come forward.
What is a lead plaintiff, and how can I seek appointment in the Badger Meter lawsuit?
A lead plaintiff in the Badger Meter class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Badger Meter investor who purchased BMI stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 3, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.
What should investors do if they purchased Badger Meter stock during the Class Period?
Investors who purchased Badger Meter (BMI) stock between April 18, 2024 and April 16, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Badger Meter securities class action is August 3, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/BMI for more information.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305459
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Planet Fitness (PLNT) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Planet Fitness common stock between November 6, 2025, and May 6, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Planet Fitness, Inc. (“Planet Fitness” or the “Company”) (NASDAQ:PLNT) in the United States District Court for the District of New Hampshire on behalf of all persons and entities who purchased or otherwise acquired Planet Fitness common stock between November 6, 2025, and May 6, 2026, both dates inclusive (the “Class Period”). Investors have until September 14, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:
The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts concerning Planet Fitness’ ability to nationally rollout its Black Card price increase, Planet Fitness’ projected membership growth outlook and associated sales growth, and its ability to drive new joins on its existing marketing campaign.On May 7, 2026, Planet Fitness released its Q1 2026 financial results. The company announced disappointing membership growth and cut 2026 revenue growth guidance from approximately 9% to about 7% and adjusted EBITDA growth guidance from roughly 10% to approximately 6%. During the same-day earnings call, the company stated that its marketing "may have pivoted too far" as the company "shift[ed] from [its] lighthearted approachable tone" to one that "increased penetration with the fitness-minded." As such it announced that, "we are pausing the planned national Black Card price increase pending a broader pricing review."This news caused the price of Planet Fitness stock to decline $19.95 per share, or 31%, from a closing price of $63.96 per share on May 6, 2026, to $44.01 per share on May 7, 2026. Next Steps:
If you purchased or otherwise acquired Planet Fitness shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Simply Good Foods Company ("Simply Good" or the "Company") (NASDAQ: SMPL).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are a Simply Good investor and have suffered losses, or if you have information that could assist in the Simply Good investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
On June 13, 2024, Simply Good announced the completion of the acquisition of Only What You Need (OWYN) for a purchase price of $280 million.
On October 23, 2025, Simply Good reported financial results for the fourth quarter of 2025, disclosing among other things, a "quality issue" with the Company's recently acquired OWYN brand, "related to a raw material sourcing decision for pea protein made prior to the closing of the acquisition."
Following this news, the price of Simply Good stock fell $4.33 per share, or 17.35%, to close at $20.63 per share on October 23, 2025
Then, on April 9, 2026, Simply Good reported financial results for the second quarter of 2026, including that "Net sales of $326.0 million decreased 9.4% versus the comparable year ago period, driven by declines for Atkins and OWYN of 26.6% and 16.8%, respectively." Simply Good also "recognized an aggregate $249.0 million non-cash, impairment charge related to the Atkins brand and OWYN brand intangible assets" comprised of "a loss on impairment $187.0 million for OWYN and $62.0 million for Atkins[.]"
Following this news, the price of Simply Good stock fell $2.61 per share, or 18.11%, to close at $11.80 per share on April 9, 2026.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this investigation, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement to their employment.
The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $82.62 per share, which is equal to the closing price of the Company’s common stock on July 15, 2026 and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.
The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to discuss the results with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.
Investors seeking exposure to future-leaning technologies often weigh the potential of urban air mobility against satellite-to-phone connectivity when comparing Archer Aviation (ACHR 0.78%) and AST SpaceMobile (ASTS +5.07%) for their growth portfolios.
Archer Aviation focuses on "flying taxis" to bypass ground traffic, while AST SpaceMobile aims to eliminate global dead zones by providing satellite cellular service. Both companies represent ambitious, capital-intensive bets on infrastructure. Choosing between them requires understanding their different paths to regulatory approval, their distinct manufacturing hurdles, and their current financial health as they move toward commercial scale.
The case for Archer AviationArcher Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for commercial and military use. This growth among industrial stocks is anchored by the United Purchase Agreement, providing for the conditional purchase of up to $1.0 billion in Midnight aircraft from United Airlines Holdings (UAL 2.86%). The company also partners with the U.S. Air Force and Stellantis (STLA 2.85%) for manufacturing support.
In FY 2025, Archer Aviation reported revenue of $300,000. This early-stage revenue was accompanied by a net loss of approximately $618.2 million. This reflects a company still in its pre-commercial phase as it pursues aircraft type and production certification.
As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.1x. This ratio measures total debt, including short- and long-term obligations, against shareholders' equity, with a lower number indicating less reliance on borrowed money. Free cash flow was negative at $511.7 million, representing the cash remaining after operating and capital spending are covered.
The case for AST SpaceMobileAST SpaceMobile builds a space-based cellular broadband network that connects standard smartphones directly to satellites. Its model relies on strategic partnerships with mobile network operators like AT&T (T 0.77%) and Verizon Communications (VZ 0.66%). These agreements provide access to nearly 3 billion subscribers globally through the partner network, bypassing the need for traditional customer acquisition.
In FY 2025, revenue reached approximately $70.9 million, a substantial jump from the $4.4 million reported in the prior fiscal year. The company reported a net loss of nearly $342 million for the period. While revenue growth is accelerating as the company begins its commercial rollout, profitability remains a distant goal during this build-out phase.
The current debt-to-equity ratio is roughly 1.2x, showing the company relies more on debt than equity to fund its operations. Free cash flow, which is cash flow from operations minus capital expenditures, was more than negative $1.1 billion for FY 2025, reflecting heavy investment in its satellite constellation.
Risk profile comparisonArcher Aviation faces substantial regulatory certification risk, as it must secure FAA type and production certificates before launching commercial service. The business is highly capital-intensive, requiring frequent cash infusions that could lead to dilution or debt. It also faces competition from well-funded aerospace incumbents like Boeing Co. (BA 0.14%) and other eVTOL developers.
AST SpaceMobile depends on the successful launch and deployment of satellites, where any malfunction could delay service or cause total losses. The company relies heavily on mobile network operators to market its services, creating a dependency on third-party performance. Furthermore, it competes against established providers like Amazon.com Inc (AMZN 0.91%) and regional satellite providers in the race for global connectivity.
Valuation comparisonBased on future earnings estimates and the Forward P/E ratio, Archer Aviation looks more affordable than AST SpaceMobile despite its higher P/S ratio.
MetricArcher AviationAST SpaceMobileSector BenchmarkForward P/En/an/a240.6xP/S ratio1,160x177xSector benchmark uses the SPDR XLI sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Last year, the U.S. federal government created the framework for real-world testing of eVTOL aircraft, a concrete step toward making Archer's vision a reality. Japan, South Korea, and Saudi Arabia are other countries building similar regulatory frameworks. A lot still has to happen for Archer’s aircraft to get into the skies, but the notion that the nation's airspace is being regulated in a way that is holding back growth is one that has found favor.
Archer is taking steps to refurbish a small Los Angeles airport for use as its testing grounds and is working to scale up its manufacturing capabilities to eventually reach capacity for 50 planes a year. Management has an initial plan to focus on military and cargo uses for its plane, which would be an easier path to early revenue. It's highly speculative, but Wall Street analysts see Archer turning its first profit in 2030, with $2.3 billion in revenue, but a lot has to go right between now and then.
AST SpaceMobile is a very different business from Archer. Essentially, AST SpaceMobile is a direct-to-device play, providing full mobile phone compatibility with major carriers without the need for specialized equipment. Many of its potential clients are also shareholders in the company, including AT&T, Verizon, Vodafone (VOD +0.74%), Alphabet (GOOGL 2.05%), American Tower (AMT +0.68%), Telus (TU 1.79%), Bell Canada, and Rakuten.
By the end of the year, the company expects to have 45 satellites in orbit, which will allow it to fully service the U.S., and that should start to supercharge revenue growth. For fiscal 2026, Wall Street sees $149 million in sales, jumping to $725 million the following year, when the company is projected to turn its first modest profit. Free cash flow appears much more manageable, with analysts expecting positive free cash flow in 2029.
Air taxis and electric planes are promising businesses for Archer, but the airline business has shown that there are very few competitive moats in the long run. Coupled with its long runway to significant revenue generation, it’s a wait-and-see stock right now.
AST SpaceMobile, on the other hand, does have the burden of very high capital expenditures right now, but it has a fairly high competitive moat for its space-based network. Its roster of telco investors and quick path to revenue growth starting next year make it the stock to buy in 2026.
Ending the week on a bullish note, AST SpaceMobile (ASTS +5.25%) stock closed higher today after an analyst provided an optimistic outlook. Shares of AST SpaceMobile, a developer of a space-based cellular broadband service, had fallen 10.6% from the end of trading last Friday through yesterday's close.
Today, however, shares of AST SpaceMobile closed up 5.1%, retreating from an earlier rise of 12.1%.
Image source: Getty Images.
One analyst sees this space stock flying notably higher Maintaining his $85 price target on AST SpaceMobile, B. Riley analyst Mike Crawford upgraded AST SpaceMobile stock to buy from neutral today. With shares falling more than 50% over the past six months, Crawford now believes that AST SpaceMobile stock provides investors with a better risk/reward profile, according to Thefly.com.
Today's Change
(
5.25
%) $
2.89
Current Price
$
57.90
Based on AST SpaceMobile stock closing at $55.01 yesterday, Crawford's price target implies upside of 54.5%.
B. Riley isn't the only firm espousing positivity for AST SpaceMobile this week. On Wednesday, Piper Sandler initated coverage on AST SpaceMobile with an overweight rating and $100 price target.
Is now the time to buy AST SpaceMobile stock? Analysts may have see AST SpaceMobile stock rocketing higher, but investors should take these price targets with grains of salt. While analysts' opinions are worth considering, investors are better served to exercise their due diligence and look for the company to report developments that are material to its growth such as progress toward the launch of its broadband service. As one of SpaceX's most notable competitors, AST SpaceMobile certainly deserves consideration from space stock enthusiasts.
Scott Levine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AST SpaceMobile. The Motley Fool has a disclosure policy.
On Thursday, July 16, during the broadcast of Mad Money , Jim Cramer pushed back on the market's punishment of several blue-chip companies that just posted strong quarters.
July 17, 2026 17:15 ET | Source: Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 139,930 shares of Iovance’s common stock to seventeen new, non-executive employees.
The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $4.66, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to assist with the transition. The company will conduct a search for her permanent successor, with Yemi Okupe, CFO of Hims & Hers, assuming the responsibilities of CAO in the interim.
"Irene has left an indelible mark on Hims & Hers as a trusted leader whose expertise and judgment have been integral to our growth as a company. Over the last seven years, Irene has helped build and maintain the financial discipline, technical rigor, and high standards that define our organization today. I'm deeply grateful for everything she has contributed and for the opportunity to have worked alongside her. She has earned a well-deserved break, and we wish her nothing but the best in what comes next," said Okupe.
Becklund joined Hims & Hers in 2019 as the company’s first Controller. She has played a pivotal role in building and scaling the company's financial reporting and public company infrastructure. During her tenure, she has helped to guide the company through many of its most significant milestones, including its IPO, strategic acquisitions, and international expansion.
About Hims & Hers Health, Inc
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.
Sweetgreen stock jumped 15% Friday, paring back a massive four-day slump, after regulators traced an explosive diarrhea outbreak back to Taco Bell restaurants – sparing the salad bowl chain’s reputation.
The fast-casual salad chain – known for its so-called “slop bowls” – saw its stock soar as much as 21% Friday for its biggest intraday gain since August 2024.
It plummeted nearly 26% from Monday through Thursday’s close as investors feared consumers would steer clear of fresh produce as thousands of people across several US states were sickened by cyclosporiasis.
Sweetgreen – known for its so-called “slop bowls” – saw its stock soar as much as 21% Friday. Boston Globe via Getty Images The Centers for Disease Control and Prevention and the Food and Drug Administration said late Thursday that they had linked the outbreak to shredded iceberg lettuce served at a handful of Taco Bell restaurants in Indiana, Kentucky, Michigan, Ohio and West Virginia.
On Friday, Bloomberg reported that Taylor Farms, a California-based fresh produce supplier, is preparing to recall ingredients linked to the outbreak.
“Sweetgreen does not use iceberg lettuce in our menu,” a spokesperson for Sweetgreen said in a statement.
“From the outset of the investigation, we have been in close contact with our suppliers to determine whether any ingredients in our supply chain have been identified as part of the investigation. To date, none have been.”
Shares of Sweetgreen are still down nearly 15% this week, while Taco Bell has fallen about roughly 8% during the same timeframe – similarly regaining some losses after the fast-food giant said it has removed lettuce from the tainted supplier nationwide.
The FDA said it was able to link the outbreak to the burrito-and-taco chain after more than 1,644 sick people suffering from cyclosporiasis reported eating at Taco Bell locations in five states.
Shares of Sweetgreen are still down nearly 15% this week. Ai – stock.adobe.com Regulators said they are working directly with the unnamed supplier – now reportedly believed to be Taylor Farms – to determine if the contaminated iceberg lettuce was sent to any other partners.
Cyclospora is a microscopic parasite that is typically transmitted when infected feces contaminates food or water, according to the FDA.
It can cause an intestinal illness called cyclosporiasis, characterized by symptoms like watery diarrhea, loss of appetite, weight loss, stomach cramps or pain, bloating, gas, nausea and fatigue, according to food safety regulators. Some people may become infected and be asymptomatic.
The main risk from cyclosporiasis is dehydration that can lead to more serious complications. Those most at risk include people with weakened immune systems, the elderly and children.
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571.
Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"
On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik® (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged." As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."
Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Jim Cramer believes forced selling is creating opportunities, but investors should resist buying too early. During his July 17, 2026, Mad Money Lightning Round, he recommended two defensive dividend stocks while urging patience on semiconductors and highly speculative names. His message was simple: “The speculative hands are being margined out. They’re going to get rid of them, and you’ll get a better price if you want to buy.“
Wait to Buy Semiconductors Until the Margin Sellers Are Gone On a caller’s semiconductor question, Cramer advised being patient: “It’s a semiconductor and all semiconductor stocks are going down. May I suggest that you wait a few more days until we get rid of all the margin players, and you’re going to find a bottom. I don’t see it yet.”
NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) fundamentals remain intact. Q1 FY2027 delivered $81.61B in revenue, up 85.2% YoY, with Data Center revenue of $75.25B. But Polymarket assigns only a 60.5% probability that NVDA closes above $200 by end of July and just 37% above $210. Reddit sentiment fell into bearish territory (scores 32 to 46) July 7 through 9 on DeepSeek chip news and server delay reports.
Cramer Warns Nebius Is “Not Done Going Down” Cramer’s sharpest warning targeted Nebius Group (NASDAQ:NBIS): “It is at the nexus of the craziness right now. There are a lot of hedge funds that own it, and I think they’re in a lot of trouble. This stock is not done going down. There’ll be another time to buy it, but that time is not now.”
Shares fell 35.21% over the past month and 20.55% in the past week, closing at $171.77 on July 16. Fundamentals are strong (Q2 revenue of $399M, up 279.6% YoY, an NVIDIA $2B pre-funded warrant investment, and a $12B Meta contract), but shares trade at 57.7x sales and 68x forward earnings.
Cramer Says Clorox’s 5% Yield Is Finally Worth Buying Cramer’s headline call was on Clorox (NYSE:CLX). “I read my first positive note about Clorox in a great deal of time today. That was a price target increase that made me say 5% yield. You know what? We want to buy it.“
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Clorox pays $1.24 quarterly, or $4.96 annualized, translating to a 5.12% yield. Shares closed at $98.71 on July 16, down 18.67% over the past year. The stock trades at 15x forward earnings with a 0.53 beta, making it a classic defensive setup Cramer wants against margin-driven volatility.
Fiscal Q3 delivered mixed signals. Adjusted EPS came in at $1.64, beating the $1.55 estimate, though management sharply lowered FY2026 guidance to $5.45-$5.65 in adjusted EPS, citing ERP transition, inventory normalization, and GOJO integration dilution as drivers of organic sales declines. CEO Linda Rendle called results “mixed, with continued momentum in some parts of our portfolio and slower-than-anticipated market share recovery in others.”
Why Cramer Prefers Coca-Cola Over Its Largest Bottler Asked about the bottlers, Cramer chose the parent: “I would go for Coke. I think that’s a better stock.” Coca-Cola (NYSE:KO) is up 23.1% year to date, delivered Q1 EPS of $0.86 on 12.1% revenue growth, and pays $0.53 quarterly. Coca-Cola Consolidated posted a 70 bps gross margin contraction due to aluminum tariff costs and yields materially less on its $0.25 quarterly payout.
Quanta’s $48.5 Billion Backlog Makes This Selloff Worth Watching Quality cyclicals aren’t immune. Quanta Services (NYSE:PWR) has come down from $788 to $630, retracing 12.26% in a month even after posting a record $48.5B backlog. Cramer’s advising for investors to let leveraged sellers finish selling, then step into names where cash flow, dividends, and backlog do the heavy lifting.
Key Takeaways Cramer sees Clorox and Coca-Cola as dependable defensive holdings, while semiconductors may become attractive once forced selling subsides. More speculative names such as Nebius could have further to fall. The opportunity, in Cramer’s view, will come after leveraged sellers have been cleared out and strong businesses can be purchased at more attractive prices.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Key Takeaways D-Wave Quantum has fallen 29.4% in July amid profit-taking, valuation concerns and macro headwinds.QBTS plans a Nasdaq listing transfer and expanded quantum research with an NSF-backed subsidiary grant.QBTS faces weak technical signals as investors await second-quarter earnings and further execution updates. The sharp pullback in D-Wave Quantum (QBTS - Free Report) this month has shifted investor attention from the quantum computing sector's long-term promise to its near-term execution risks. After delivering substantial gains earlier this year, the stock has fallen 29.4% month to date, underperforming the Computer and Technology sector's 1.4% decline and the S&P 500's 1.2% gain.
The weakness reflects a combination of profit-taking after the stock's outsized gains earlier this year, valuation concerns across high-growth quantum names and a macroeconomic backdrop marked by elevated U.S. Treasury yields and expectations that the Federal Reserve will keep interest rates higher for longer. These conditions have weighed disproportionately on speculative technology stocks despite continued enthusiasm for artificial intelligence and quantum computing.
During the same period, QBTS' pure-play quantum computing peers, IonQ (IONQ - Free Report) and Rigetti Computing (RGTI - Free Report) , also witnessed sharp share price declines of 34.1% and 27%, respectively.
Month-to-Date Share Price Comparison
Image Source: Zacks Investment Research
Will July Catalysts Change QBTS' Trajectory?D-Wave Quantum will report its second-quarter earnings in early August. While the stock has remained under pressure amid a broader selloff of speculative growth companies, the company's strategic execution continues to advance. Most notably, D-Wave announced plans to transfer its listing from the NYSE to the Nasdaq later this month, a move expected to enhance its visibility among technology-focused investors and potentially broaden its shareholder base. The company also disclosed that its Quantum Circuits subsidiary received a U.S. National Science Foundation grant to support research in fault-tolerant quantum computing, further strengthening D-Wave's expansion beyond quantum annealing into gate-model quantum systems.
The broader industry backdrop also remains constructive. NVIDIA (NVDA - Free Report) recently introduced an open-source AI decoder that significantly improves quantum error-correction performance, while IBM reaffirmed plans to invest more than $10 billion in quantum technologies over the coming years. Meanwhile, governments across the United States and Europe continue to expand funding for quantum research and commercialization. These developments strengthen the long-term growth opportunity for the sector, although they are yet to offset near-term concerns surrounding elevated valuations, higher Treasury yields and a "higher-for-longer" interest-rate environment that continues to put pressure on pre-profit technology companies.
What Do the Estimates Say?The earnings estimate chart indicates that D-Wave is expected to report a second-quarter loss of 8 cents per share, representing an 85.5% improvement from the year-ago quarter. For full-year 2026, the consensus estimate calls for a loss of 25 cents per share, reflecting a 77.5% improvement from 2025. Despite the broader market selloff, the absence of estimate revisions suggests that analysts have adopted a wait-and-see stance ahead of the company's second-quarter earnings release.
Image Source: Zacks Investment Research
Technical Pressure RemainsThe technical picture remains weak. As the chart shows, QBTS is trading well below both its 50-day SMA and 200-day SMA, indicating sustained bearish momentum. While the sharp correction reflects deteriorating near-term sentiment, upcoming catalysts, including the Nasdaq listing transition and second-quarter earnings, could determine whether the stock stabilizes or extends its decline.
QBTS 50-&-200-Day SMAs
Image Source: Zacks Investment Research
Our TakeDespite near-term macro headwinds and a weak technical setup, D-Wave's strengthening fundamentals and strategic execution support a constructive long-term outlook. The planned Nasdaq listing, continued expansion into gate-model quantum computing and strong earnings expectations position the company favorably ahead of its second-quarter results. Consistent with its Zacks Rank #2 (Buy), we believe the recent pullback offers a buying opportunity for investors willing to look beyond near-term volatility, while recognizing that technical weakness may persist until fresh business catalysts emerge. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
If you are a long-term SMMT stockholder please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the “Start Date”). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock (“Common Stock”) with a per share exercise price of $4.78, the closing trading price of the Common Stock on the Nasdaq Global Market on July 16, 2026 (the “Closing Price”). The stock option was granted pursuant to the Company’s 2025 Employment Inducement Award Plan (the “Inducement Plan”) and was approved by the Company’s Board of Directors (the “Board”). The stock option has a ten-year term and vests (subject to Mr. Gengos’s continued service to the Company through the applicable vesting dates) as follows: 8.33333% of the initial shares underlying the option shall vest on each of the first, second and third monthly anniversary of the Start Date; 1.6667% of the initial shares underlying the option shall vest on the fourth monthly anniversary of the Start Date and on each monthly anniversary thereafter until the one-year anniversary of the Start Date; 3.33333% of the initial shares underlying the option shall vest on each monthly anniversary following the one-year anniversary of the Start Date until the second anniversary of the Start Date; and 0.833333% of the of the initial shares underlying the option shall vest on each monthly anniversary following the second anniversary of the Start Date until the fourth anniversary of the Start Date, such that the stock option shall be fully vested and exercisable on the fourth anniversary of the Start Date. The stock option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules (the “Nasdaq Rules”) as an inducement material to Mr. Gengos entering into employment with the Company.
Additionally, in connection with the commencement of employment of a non-executive employee, also on July 16, 2026, such employee was granted an option to purchase 32,400 shares of Common Stock with a per share exercise price equal to the Closing Price. The stock option was granted pursuant to the Inducement Plan and was approved by the Compensation Committee of the Board. The stock option has a ten-year term and vests (subject to the employee’s continued service to the Company through the applicable vesting dates) 25% on July 16, 2027 and the remaining 75% in substantially equal monthly installments over the three years thereafter, such that the stock option shall be fully vested and exercisable on July 16, 2030. The stock option was granted under the Nasdaq Rules as an inducement material to the employee entering into employment with the Company.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.
Forward Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: Immuneering’s plans to develop, and the treatment potential of, its product candidates.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in activating trial sites or enrolling trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended March 31, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 25, 2026 to file lead plaintiff applications in a securities class action lawsuit against Futu Holdings Limited ("Futu" or the "Company") (NASDAQ: FUTU), if they purchased or otherwise acquired the Company's securities between May 24, 2023 and May 27, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=Tmjc32xVGrk
What You May Do
If you purchased securities of Futu as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgm-futu/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 25, 2026.
>>>CLICK HERE for more information
About the Lawsuit
Futu and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company was not in compliance with the requirements of the China Securities Regulatory Commission, including because it continued to conduct securities business, public fund sales business and futures business in mainland China without obtaining the requisite licenses or approval; (ii) as a result, the Company was reasonably likely to face regulatory penalties, including the disgorgement of ill-gotten gains and other penalties; (iii) as a result of the foregoing, the Company's financial results were overstated; and (iv) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
The case is Tang v. Futu Holdings Limited, et al, 26-cv-05453.
>>>To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
>>>For More Information about the case, Click HERE
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner [email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163
